What's Happening?
The 21st Edition Project Portfolio and Resource Management Excellence for Pharma and BioTech conference is set to take place in New Jersey from May 7 to May 8, 2026. This event, organized by Marcus Evans, will focus on how leading pharmaceutical and biotech
companies are enhancing their portfolio decision-making frameworks in response to increasing regulatory pressures, investment constraints, and scientific uncertainties. The conference will feature discussions on governance discipline, cross-functional alignment, and evidence-based valuation. Attendees will explore how advanced analytics and AI are being used to improve forecasting, scenario modeling, and risk assessment. The event will also address operational challenges such as resource bottlenecks, shifting strategic priorities, and accelerated development timelines. Senior leaders from companies like Daiichi Sankyo, Novartis, Merck, argenx, AstraZeneca, and Boehringer Ingelheim will share best practices for maintaining R&D competitiveness and future-proofing portfolios against market disruptions.
Why It's Important?
This conference is significant as it addresses the critical need for pharmaceutical and biotech companies to adapt to a rapidly changing regulatory and economic environment. With increasing pressures from regulatory bodies and the necessity for swift innovation, companies must refine their portfolio management strategies to remain competitive. The use of advanced analytics and AI in decision-making processes can lead to more accurate forecasting and risk assessments, ultimately improving the efficiency and effectiveness of drug development. By sharing best practices and case studies, industry leaders can learn from each other and implement strategies that balance short-term gains with long-term innovation. This collaboration is crucial for sustaining growth and ensuring that novel therapies reach patients in a timely manner, which is a pressing concern given the current pace of scientific advancements and market demands.
What's Next?
Following the conference, participating companies are likely to implement the insights and strategies discussed to enhance their portfolio management practices. This could lead to increased collaboration between companies and regulatory bodies to streamline the approval process for new therapies. Additionally, the adoption of AI and advanced analytics in portfolio management may become more widespread, leading to more data-driven decision-making in the industry. Companies may also focus on building organizational agility to better respond to market disruptions and shifting priorities. The outcomes of this conference could influence future industry standards and practices, potentially leading to more efficient drug development processes and faster delivery of innovative therapies to patients.
